UnknownNot applicableNCT05846854
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
Studying Alagille syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stanford University
- Principal Investigator
- Noelle Ebel, MDStanford University
- Intervention
- Assessment for bleeding disorder with tailored post-operative care(other)
- Enrollment
- 40 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2023 – 2024
Study locations (1)
- Stanford University, Palo Alto, California, United States
Collaborators
Alagille Syndrome Alliance
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05846854 on ClinicalTrials.govOther trials for Alagille syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07411716Pediatric Evaluation and Registry for Liver Cholestasis in CanadaChildren's Hospital of Eastern Ontario
- RECRUITINGNCT07293897A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)Takeda
- RECRUITINGPHASE4NCT07290257Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)Mirum Pharmaceuticals, Inc.
- RECRUITINGNCT06850038A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentIpsen
- RECRUITINGNCT06193928Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)Mirum Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT05035030Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeAlbireo, an Ipsen Company